Switch theme
Sign up to access all valuation multiples
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
1972
12.3K+
LTM Revenue n/a
LTM EBITDA n/a
$607M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Renata has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Renata achieved revenue of $315M and an EBITDA of $56.4M.
Renata expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Renata valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $275M | $315M | XXX | XXX | XXX |
| Gross Profit | $123M | $107M | XXX | XXX | XXX |
| Gross Margin | 45% | 34% | XXX | XXX | XXX |
| EBITDA | $37.0M | $56.4M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 18% | XXX | XXX | XXX |
| Net Profit | $42.7M | $19.5M | XXX | XXX | XXX |
| Net Margin | 16% | 6% | XXX | XXX | XXX |
| Net Debt | $67.7M | $102M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Renata's stock price is BDT 493 (or $4).
Renata has current market cap of BDT 56.5B (or $471M), and EV of BDT 72.7B (or $607M).
See Renata trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $607M | $471M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Renata has market cap of $471M and EV of $607M.
Renata's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Renata's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Renata and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $607M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.9x | XXX | XXX | XXX |
| P/E | 16.9x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | -51.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRenata's NTM/LTM revenue growth is Infinity%
Renata's revenue per employee for the last fiscal year averaged $26K, while opex per employee averaged $8K for the same period.
Over next 12 months, Renata's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Renata's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Renata and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 53% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $26K | XXX | XXX | XXX | XXX |
| Opex per Employee | $8K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Renata acquired XXX companies to date.
Last acquisition by Renata was XXXXXXXX, XXXXX XXXXX XXXXXX . Renata acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Renata founded? | Renata was founded in 1972. |
| Where is Renata headquartered? | Renata is headquartered in Bangladesh. |
| How many employees does Renata have? | As of today, Renata has 12.3K+ employees. |
| Who is the CEO of Renata? | Renata's CEO is Mr. Kaiser Kabir. |
| Is Renata publicy listed? | Yes, Renata is a public company listed on DHA. |
| What is the stock symbol of Renata? | Renata trades under RENATA ticker. |
| Who are competitors of Renata? | Similar companies to Renata include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Renata? | Renata's current market cap is $471M |
| What is the current revenue growth of Renata? | Renata revenue growth between 2023 and 2024 was 14%. |
| Is Renata profitable? | Yes, Renata is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
